350 related articles for article (PubMed ID: 23109727)
41. Novel extraneural role of neurite outgrowth inhibitor A: modulation of osteoclastogenesis via positive feedback regulation of nuclear factor of activated T cell cytoplasmic 1.
Lee Y; Kim HJ; Park CK; Kim WS; Lee ZH; Kim HH
J Bone Miner Res; 2012 May; 27(5):1043-54. PubMed ID: 22392845
[TBL] [Abstract][Full Text] [Related]
42. REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation.
Song C; Tan P; Zhang Z; Wu W; Dong Y; Zhao L; Liu H; Guan H; Li F
FASEB J; 2018 Jun; 32(6):3215-3228. PubMed ID: 29401617
[TBL] [Abstract][Full Text] [Related]
43. Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
Kim JY; Oh HM; Kwak SC; Cheon YH; Lee MS; Rho MC; Oh J
Biol Pharm Bull; 2015; 38(1):66-74. PubMed ID: 25744460
[TBL] [Abstract][Full Text] [Related]
44. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
[TBL] [Abstract][Full Text] [Related]
45. Amyloid β Peptide Enhances RANKL-Induced Osteoclast Activation through NF-κB, ERK, and Calcium Oscillation Signaling.
Li S; Yang B; Teguh D; Zhou L; Xu J; Rong L
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27735865
[TBL] [Abstract][Full Text] [Related]
46. 3',4',7,8-Tetrahydroxyflavone inhibits RANKL-induced osteoclast formation and bone resorption.
Kang JH; Jung H; Yim M
Pharmazie; 2017 Mar; 72(3):161-166. PubMed ID: 29442051
[TBL] [Abstract][Full Text] [Related]
47. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
[TBL] [Abstract][Full Text] [Related]
48. Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention.
Sun X; Zhang J; Wang Z; Liu B; Zhu S; Zhu L; Peng B
Theranostics; 2019; 9(18):5183-5199. PubMed ID: 31410209
[TBL] [Abstract][Full Text] [Related]
49. NADPH oxidase gp91
Kang IS; Kim C
Sci Rep; 2016 Nov; 6():38014. PubMed ID: 27897222
[TBL] [Abstract][Full Text] [Related]
50. Protein kinase C inhibitor, GF109203X attenuates osteoclastogenesis, bone resorption and RANKL-induced NF-κB and NFAT activity.
Yao J; Li J; Zhou L; Cheng J; Chim SM; Zhang G; Quinn JM; Tickner J; Zhao J; Xu J
J Cell Physiol; 2015 Jun; 230(6):1235-42. PubMed ID: 25363829
[TBL] [Abstract][Full Text] [Related]
51. Mitogen- and stress-activated protein kinase 1 activates osteoclastogenesis in vitro and affects bone destruction in vivo.
Ha J; Kim HJ; Huang H; Lee ZH; Kim HH
J Mol Med (Berl); 2013 Aug; 91(8):977-87. PubMed ID: 23619911
[TBL] [Abstract][Full Text] [Related]
52. Piperine alleviates osteoclast formation through the p38/c-Fos/NFATc1 signaling axis.
Deepak V; Kruger MC; Joubert A; Coetzee M
Biofactors; 2015; 41(6):403-13. PubMed ID: 26627060
[TBL] [Abstract][Full Text] [Related]
53. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of RANKL- and LPS-induced osteoclast differentiations by novel NF-κB inhibitor DTCM-glutarimide.
Koide N; Kaneda A; Yokochi T; Umezawa K
Int Immunopharmacol; 2015 Mar; 25(1):162-8. PubMed ID: 25617668
[TBL] [Abstract][Full Text] [Related]
55. Dynein light chain LC8 inhibits osteoclast differentiation and prevents bone loss in mice.
Kim H; Hyeon S; Kim H; Yang Y; Huh JY; Park DR; Lee H; Seo DH; Kim HS; Lee SY; Jeong W
J Immunol; 2013 Feb; 190(3):1312-8. PubMed ID: 23293355
[TBL] [Abstract][Full Text] [Related]
56. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
[TBL] [Abstract][Full Text] [Related]
57. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation.
Song I; Kim JH; Kim K; Jin HM; Youn BU; Kim N
FEBS Lett; 2009 Jul; 583(14):2435-40. PubMed ID: 19576893
[TBL] [Abstract][Full Text] [Related]
58. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
[TBL] [Abstract][Full Text] [Related]
59. 9-Hydroxy-6,7-dimethoxydalbergiquinol inhibits osteoclast differentiation through down-regulation of Akt, c-Fos and NFATc1.
Kim JY; Kim JY; Cheon YH; Kwak SC; Baek JM; Kim YC; Yoon KH; Oh J; Lee MS
Int Immunopharmacol; 2014 May; 20(1):213-20. PubMed ID: 24630975
[TBL] [Abstract][Full Text] [Related]
60. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
